Validation of senescence as a therapeutic target in metabolic dysfunction-associated steatohepatitis (MASH) through navitoclax delivery.
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by steatosis, inflammation, and progressive fibrosis. Increasing evidence suggests that cellular senescence contributes to MASH progression by promoting lipid accumulation, inflammatory signaling, and fibrogenic responses,...